open access

Vol 16, No 2 (2009)
Original articles
Published online: 2009-01-06
Submitted: 2013-01-14
Get Citation

Evaluation of exercise capacity with cardiopulmonary exercise test and B-type natriuretic peptide in adults with congenital heart disease

Olga Trojnarska, Adrian Gwizdała, Sławomir Katarzyński, Agnieszka Katarzyńska, Andrzej Szyszka, Magdalena Lanocha, Stefan Grajek, Lucyna Kramer
Cardiol J 2009;16(2):133-141.

open access

Vol 16, No 2 (2009)
Original articles
Published online: 2009-01-06
Submitted: 2013-01-14

Abstract

Background: Adult patients with congenital heart disease (CHD) usually find their exercise capacity satisfactory. However, objective evaluation is important for diagnostic and prognostic purposes. The aim of this study was to evaluate exercise capacity using cardiopulmonary exercise tests and measurement of serum B-type natriuretic peptide (BNP) levels in adult patients with CHDs, both in the entire study cohort and in subjects with individual types of cardiac lesions, as well as to verify the relation between BNP level and cardiac performance.
Methods: The study group included 265 patients (136 males; mean age 34.4 ± 11.6 years) 173 of whom were operated on at the mean age of 9.2 ± 7.3 years. They represented the following types of CHD: 72 patients - surgically corrected coarctation of the aorta, 62 - surgically corrected tetralogy of Fallot, 28 - Ebstein anomaly, 26 - patent atrial septal defect, 24 - Eisenmenger syndrome, 20 - uncorrected or palliated complex cyanotic lesions, 11 - corrected transposition of the great arteries (TGA), 14 - TGA after Senning operation, and 8 - common ventricle after Fontana operation. The control group consisted of 39 healthy individuals (17 males) with a mean age of 35.8 ± 9.3 years.
Results: According to NYHA classification, 207 patients were recognized as representing class I symptoms, 47 subjects class II, and 11 class III. Cardiopulmonary exercise revealed significantly reduced exercise capacity in adults with CHD in general, compared to control subjects: maximal oxygen uptake (VO2max) was 23.3 ± 6.9 vs. 33.6 ± 7.2 mL/kg/min, respectively (p = 0.00001); maximum heart rate at peak exercise (HRmax) -161.1 ± 33.2 vs. 179.6 ± 12.3 bpm (p = 0.00001); respiratory workload (VE/VCO2slope) - 35.7 ± 9.7 vs. 26.3 ± 3.1 (p = 0.00001); and forced vital capacity (FVC) - 3.8 ± 1.1 vs. 4.6 ± 0.7 L (p = = 0.00003). Various degrees of peak VO2max reduction were observed across the spectrum of CHD. Patients after repair of aortic coarctation demonstrated the highest VO2max (26.8 ± 6.6 mL/kg/min), and the lowest was demonstrated by patients with Eisenmenger syndrome (12.8 ± 4.8; ANOVA p = 0.00001). Serum BNP levels in the study group were higher than in the controls: 55.4 ± 67.5 vs. 13.9 ± 13.7 pg/mL, respectively (p = 0.00001). Various degrees of BNP level increase were found across the spectrum of CHD. Patients after repair of aortic coarctation demonstrated the lowest BNP level (24.8 pg/mL), and the highest level was found in patients with cyanotic defects (120.7 pg/mL; ANOVA p = 0.00001). BNP levels across the NYHA classes were as follows: I - 35.7 pg/mL, II - 94.1 pg/mL, and III - 225.6 pg/mL. BNP levels showed negative correlation with VO2max (r = –0.525, p = 0.0001), FVC (r = = –0.349, p = 0.00001), FEV1 (r = –0.335, p= 0.00001), and positive correlation with VE/VCO2slope (r = 0.447, p = 0.00001).
Conclusions: The exercise capacity of patients with CHD is, in general, compromised, most strikingly in patients suffering from pulmonary hypertension and cyanosis. Serum BNP levels in these subjects are increased and correlate well with exercise capacity. BNP level is higher in patients with cyanotic CHDs.

Abstract

Background: Adult patients with congenital heart disease (CHD) usually find their exercise capacity satisfactory. However, objective evaluation is important for diagnostic and prognostic purposes. The aim of this study was to evaluate exercise capacity using cardiopulmonary exercise tests and measurement of serum B-type natriuretic peptide (BNP) levels in adult patients with CHDs, both in the entire study cohort and in subjects with individual types of cardiac lesions, as well as to verify the relation between BNP level and cardiac performance.
Methods: The study group included 265 patients (136 males; mean age 34.4 ± 11.6 years) 173 of whom were operated on at the mean age of 9.2 ± 7.3 years. They represented the following types of CHD: 72 patients - surgically corrected coarctation of the aorta, 62 - surgically corrected tetralogy of Fallot, 28 - Ebstein anomaly, 26 - patent atrial septal defect, 24 - Eisenmenger syndrome, 20 - uncorrected or palliated complex cyanotic lesions, 11 - corrected transposition of the great arteries (TGA), 14 - TGA after Senning operation, and 8 - common ventricle after Fontana operation. The control group consisted of 39 healthy individuals (17 males) with a mean age of 35.8 ± 9.3 years.
Results: According to NYHA classification, 207 patients were recognized as representing class I symptoms, 47 subjects class II, and 11 class III. Cardiopulmonary exercise revealed significantly reduced exercise capacity in adults with CHD in general, compared to control subjects: maximal oxygen uptake (VO2max) was 23.3 ± 6.9 vs. 33.6 ± 7.2 mL/kg/min, respectively (p = 0.00001); maximum heart rate at peak exercise (HRmax) -161.1 ± 33.2 vs. 179.6 ± 12.3 bpm (p = 0.00001); respiratory workload (VE/VCO2slope) - 35.7 ± 9.7 vs. 26.3 ± 3.1 (p = 0.00001); and forced vital capacity (FVC) - 3.8 ± 1.1 vs. 4.6 ± 0.7 L (p = = 0.00003). Various degrees of peak VO2max reduction were observed across the spectrum of CHD. Patients after repair of aortic coarctation demonstrated the highest VO2max (26.8 ± 6.6 mL/kg/min), and the lowest was demonstrated by patients with Eisenmenger syndrome (12.8 ± 4.8; ANOVA p = 0.00001). Serum BNP levels in the study group were higher than in the controls: 55.4 ± 67.5 vs. 13.9 ± 13.7 pg/mL, respectively (p = 0.00001). Various degrees of BNP level increase were found across the spectrum of CHD. Patients after repair of aortic coarctation demonstrated the lowest BNP level (24.8 pg/mL), and the highest level was found in patients with cyanotic defects (120.7 pg/mL; ANOVA p = 0.00001). BNP levels across the NYHA classes were as follows: I - 35.7 pg/mL, II - 94.1 pg/mL, and III - 225.6 pg/mL. BNP levels showed negative correlation with VO2max (r = –0.525, p = 0.0001), FVC (r = = –0.349, p = 0.00001), FEV1 (r = –0.335, p= 0.00001), and positive correlation with VE/VCO2slope (r = 0.447, p = 0.00001).
Conclusions: The exercise capacity of patients with CHD is, in general, compromised, most strikingly in patients suffering from pulmonary hypertension and cyanosis. Serum BNP levels in these subjects are increased and correlate well with exercise capacity. BNP level is higher in patients with cyanotic CHDs.
Get Citation

Keywords

cardiopulmonary exercise testing; congenital heart disease; natriuretic peptide type B

About this article
Title

Evaluation of exercise capacity with cardiopulmonary exercise test and B-type natriuretic peptide in adults with congenital heart disease

Journal

Cardiology Journal

Issue

Vol 16, No 2 (2009)

Pages

133-141

Published online

2009-01-06

Bibliographic record

Cardiol J 2009;16(2):133-141.

Keywords

cardiopulmonary exercise testing
congenital heart disease
natriuretic peptide type B

Authors

Olga Trojnarska
Adrian Gwizdała
Sławomir Katarzyński
Agnieszka Katarzyńska
Andrzej Szyszka
Magdalena Lanocha
Stefan Grajek
Lucyna Kramer

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: viamedica@viamedica.pl